SSX2 and hepatocellular carcinoma: Among patients with early-stage HCC, the strongest response was against SALL4 (66.88 ± 22.23 SFUs/106 cells), followed by MAGE-A3 (32.16 ± 14.95 SFUs/106 cells), NY-ESO-1 (22.21 ± 10.32 SFUs/106 cells), MAGE-A1(18.21 ± 6.79 SFUs/106 cells) and SSX2 (12.84 ± 6.38 SFUs/106 cells), while the AFP-specific T cell response was relatively low (only 18.88 ± 10.01 SFUs/106 cells).